HepaRegeniX GmbH Raises €9 million in a Series A Financing to Develop Kinase Inhibitors for the Treatment of Acute and Chronic Liver Diseases
HepaRegeniX GmbH, a new Biotech company developing innovative treatments for liver diseases, announced today the complet…